Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Recommendation of “Moderate Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has earned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, MarketBeat.com reports. Six investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have covered the stock in the last year is $32.00.

Several research firms have recently issued reports on CPRX. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Stephens set a $32.00 price objective on shares of Catalyst Pharmaceuticals in a research report on Thursday, May 7th. HC Wainwright downgraded shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and decreased their price objective for the stock from $35.00 to $31.50 in a research note on Thursday, May 28th. Cantor Fitzgerald upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a research report on Friday, March 27th. Finally, Truist Financial upgraded Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th.

Catalyst Pharmaceuticals Stock Performance

NASDAQ CPRX opened at $31.45 on Friday. The business’s 50 day moving average price is $30.93 and its 200-day moving average price is $26.50. Catalyst Pharmaceuticals has a fifty-two week low of $19.05 and a fifty-two week high of $32.56. The company has a market cap of $3.85 billion, a P/E ratio of 18.07, a P/E/G ratio of 0.96 and a beta of 0.74.

Institutional Trading of Catalyst Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the business. Parkside Financial Bank & Trust grew its holdings in shares of Catalyst Pharmaceuticals by 17.6% in the fourth quarter. Parkside Financial Bank & Trust now owns 3,138 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 469 shares during the last quarter. Oregon Public Employees Retirement Fund lifted its holdings in Catalyst Pharmaceuticals by 1.8% during the 4th quarter. Oregon Public Employees Retirement Fund now owns 26,428 shares of the biopharmaceutical company’s stock valued at $617,000 after buying an additional 472 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Catalyst Pharmaceuticals by 4.7% during the 1st quarter. PNC Financial Services Group Inc. now owns 10,554 shares of the biopharmaceutical company’s stock valued at $261,000 after buying an additional 474 shares in the last quarter. Lifestyle Asset Management Inc. boosted its position in Catalyst Pharmaceuticals by 3.4% in the 4th quarter. Lifestyle Asset Management Inc. now owns 16,835 shares of the biopharmaceutical company’s stock valued at $393,000 after buying an additional 553 shares during the period. Finally, Smartleaf Asset Management LLC boosted its position in Catalyst Pharmaceuticals by 55.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,764 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 630 shares during the period. 79.22% of the stock is currently owned by institutional investors.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).